Abstract:
Objective: The purpose of this study to exarmne the efficacy and safety doses of
ambrisentan in patient with pulmonary arterial hypertension. Background: Pulmonary
arterial hypertension is a life threatening and progressive diseases with limited treatment
option. Endothelin is a vasoconstrictor and smooth muscle cell mitogen (that plays
critical role in the pathogens and progression of P AH. Methods: In this regard the writer
uses different methods collection of data from different sources. The writer uses books,
journal, internet, company visits (RENET A) for IMS data. Result: There are five drugs
available in the international market for the treatment of P AH. By comprising all the
drugs it is found that Ambrisentan is better than all others. Conclusion: Ambrisentan
appears to improve exercise capacity, symptom, and hem dynamics in patients with
pulmonary arterial hypertension . The incidence and severity of liver enzyme
abnormalities appears to low.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.
